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Abstract: The primacy of lipids as essential components of cellular membranes is conserved across
taxonomic domains. In addition to this crucial role as a semi-permeable barrier, lipids are also
increasingly recognized as important signaling molecules with diverse functional mechanisms
ranging from cell surface receptor binding to the intracellular regulation of enzymatic cascades.
In this review, we focus on ether lipids, an ancient family of lipids having ether-linked structures
that chemically differ from their more prevalent acyl relatives. In particular, we examine ether
lipid biosynthesis in the peroxisome of mammalian cells, the roles of selected glycerolipids and
glycerophospholipids in signal transduction in both prokaryotes and eukaryotes, and finally, the
potential therapeutic contributions of synthetic ether lipids to the treatment of cancer.
Keywords: ether lipid; alkylglycerol; signaling; signal transduction; glycerolipid; glycerophospho-
lipid; apoptosis; platelet; cancer
1. Introduction
Much like many other types of organic molecules, lipids are essential for life—even
ancient life. Bacteria and Archaea kingdoms each synthesize a wide variety of structurally
diverse lipids, including many of those conserved in eukaryotes such as phospholipids and
sphingolipids [1] All lipids ranging from Archaea to Eukaryota can be divided into eight
categories: fatty acyls, glycerolipids, glycerophospholipids, sphingolipids, sterol lipids,
prenol lipids, saccharolipids and polyketides [2]. Important categories like glycerophospho-
lipids can be further subdivided into classes and subclasses according to various features
including the number of radyl chains, the type of polar headgroup and whether ester or
ether bonds are present [3].
Many of these lipids are required for the formation of the physical barrier known as
the lipid bilayer that separates primitive and more complex cells from their ever-changing
environments. The crucial nature of the maintenance, composition and permeability of
cellular membranes is not debatable, but the fact that many resident lipids in the bilayer
also serve as substrates for various enzymes that generate potent molecular signals in
multiprotein signaling cascades is not immediately apparent. Since the coining of the term
“prostaglandin” by the Swedish scientist Ulf von Euler in the 1930s [4], a multitude of
bioactive lipid mediators have been discovered that can act as signaling molecules making
this aspect of lipid function no longer considered foreign, but increasingly recognized as a
significant part of cellular behavior. Some of these signaling lipids such as diacylglycerol
(DAG) and lysophosphatidic acid (LPA) are endogenously produced by the action of
many isoforms of phospholipase enzymes, while others are derived from the oxidation of
essential, polyunsaturated fatty acids (PUFA), including arachidonic acid,ω-3 orω-6 fatty
acids. PUFA can be further oxidized into oxylipins, a large group of signaling lipids that
regulate an expansive array of metazoan vascular responses such as platelet aggregation
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and clot resolution, innate immunity and inflammation [5–7]. Bacteria also utilize lipids for
signaling purposes, but as with eukaryotes, ether lipids are relatively understudied [8–11].
In this review, the role of lipids as signaling molecules is analyzed from the lens of
one particular class of lipid found in all domains of life from the ancient Archaea to the
more complex Eukarya: the understudied and enigmatic ether lipid. Due to the presence
of other timely and comprehensive reviews [12–14], however, we will focus mainly on the
signaling properties of naturally derived glycerolipids and phosphoglycerolipids, their
synthetic mimetics designed to interfere with key signaling networks in human disease
and briefly, their abundant membrane counterparts, the plasmalogens, about which much
has been written already.
1.1. Ether Lipid Biosynthesis
Ether lipids or alkyl lipids are any lipids having an ether bond instead of the more
prevalent ester bond found in the majority of lipid classes. Alkylglycerols and phospho-
rylated alkylglycerols are a special type of glycerolipid having an ether bond at the sn-1
position of the glycerol backbone, a hydroxyl group or acyl hydrocarbon chain at the
sn-2 position and a hydroxyl group (alkylglycerol) or a phosphoryl group at the terminal
sn-3 position (e.g., 1-O-alkyl-sn-glycerol, Figure 1a or 1-O-alkyl-sn-glycero-3-phosphate,
Figure 1b). To avoid confusion caused by the many different nomenclatures for lipids and
their metabolizing enzymes, common lipids or groups of lipids are described using their
systematic names, whereas individual lipids with particular chain lengths and double bond
configurations will be referred to by their numerical common name or LipidMaps nomen-
clature. Enzymes are referred to by their traditional substrate/activity names, coupled
with their official gene symbol in parentheses when appropriate.
In mammals, ether lipids constitute about 20% of the total phospholipid mass [15]. The
early steps of ether lipid biosynthesis occur in the peroxisome, a small membrane-bound
organelle that transiently interacts with the endoplasmic reticulum (ER) [12,14,16]. The
process of ether lipid biosynthesis begins when glycerol 3-phosphate (G3P) is imported into
the lumen of the peroxisome and converted to dihydroxyacetone phosphate (DHAP) by
G3P dehydrogenase (GPD1). DHAP serves as the substrate for a DHAP acyltransferase
known as glyceronephosphate O-acyltransferase (GNPAT/DHAPAT/DAPAT) that uses
activated fatty acids in the form of acyl-CoA to create an acyl-DHAP product (Figure 2).
Acyl-DHAP is the substrate for another peroxisomal enzyme, alkylglycerone phosphate
synthase (AGPS), which exchanges the nascent acyl group with a fatty alcohol to form
the characteristic ether linkage at the sn-1 position as opposed to the more common ester
linkage. The fatty alcohol used by AGPS is derived from the reduction of endogenous
acyl-CoAs by a membrane-bound protein called fatty acyl-CoA reductase (FAR1/2) or from
pools of fatty alcohols obtained from the diet. Interestingly, a pool of fatty acid synthase
(FASN) is localized to peroxisomes that produce fatty acids (e.g., palmitate), which are
subsequently activated by an acyl-CoA synthetase and reduced by FAR1/2, imported into
the peroxisome and incorporated into ether lipids [17]. As discussed later in the oncogenesis
section, genetic disruption of either GNPAT or AGPS axes causes a major, albeit not complete,
reduction in ether lipid production. These loss-of-function data offer powerful insights
into the major contributions of both peroxisomes and the ether lipidome as a whole, but
usually do not reveal causal mechanisms centered on individual signaling pathways or
lipid species [18,19].









Figure 1. Diverse lipid families contain ether lipids. (a). Hexadecylglycerol (HG) is a monoradylglycerol (MG(O-16:0/0:0/0:0))
that is a typical alkylglycerol precursor in both prokaryotes and eukaryotes often used to construct more complex ether
lipids. (b). Alkyl-lysophosphatidic acid or alkyl-LPA (PA(O-16:0/0:0) is a group of ether-linked lipids similar to LPA. Both
alkyl-LPA and acyl-LPA bind to and activate G protein-coupled receptors, which explains their physiological signaling
roles. (c). Plasmalogens contain a vinyl ether bond at sn-1, usually an unsaturated acyl group at sn-2 and either PE or PC
at sn-3. Shown here is 1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphocholine. (d). Bacterial triglycerides often
contain isoprenoid units of branched unsaturated hydrocarbon chains attached via ether bonds. Shown is free farnesol
without ether bonds to glycerol. (e). Platelet activating factor (PAF) is a group of choline-containing ether lipids that
mainly promote pro-inflammatory signaling pathways. The acetyl group at sn-2 required for this activity is added to
alkyl-LPC by an acetyltransferase. (f). Hexadecylacetylglycerol (HAG) is a diradylglycerol (DG(O-16:0/2:0/0:0)) that is the
acetylated form of HG (Panel a. above). (g). HAG can be phosphorylated to generate 1-O-hexadecyl-2-acetyl-sn-glycero-
3-phosphate (HAGP) shown here, which is thought to compete with DAG to regulate PKC signaling and/or membrane
localization. (h). Edelfosine is a synthetic anticancer ether lipid that differs from alkyl-PC and PAF in its methyl group at sn-2
(1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine).
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Figure 2. Ether lipid biosynthesis occurs in the peroxisome and ER starting with dihydroxyacetone 
phosphate (DHAP). (1) DHAP is formed within the lumen of the peroxisome and becomes acyl-
ated by glyceronephosphate acyltransferase (GNPAT) to yield acyl-DHAP. (2) Alkylglycerone 
phosphate synthase (AGPS) replaces this acyl moiety of acyl-DHAP with an alkyl group derived 
from fatty alcohols, which are products of fatty acyl-CoA reductase 1 and 2 (FAR1/2). This reaction 
produces the first ether lipid precursor, alkyl-DHAP. (3) A membrane-spanning enzyme, peroxi-
some reductase activating PPARγ (PexRAP), reduces alkyl-DHAP and acyl-DHAP to alkyl-LPA 
(Figure 1b) and acyl-LPA respectively, before transporting these products into the ER for further 
processing. (4) Alkyl-LPA is dephosphorylated and acylated at sn-2 in the ER to form alkylacyl-
Figure 2. Ether lipid biosynthesis occurs in the peroxisome and ER starting with dihydroxyacetone
phosphate (DHAP). (1) DHAP is formed within the lumen of the peroxisome and becomes acylated
by glyceronephosphate acyltransferase (GNPAT) to yield acyl-DHAP. (2) Alkylglycerone phosphate
synthase (AGPS) replaces this moiety of acyl-DH P with an alk l group derived from fatty
alcohols, which are products of fatty acyl-CoA reductase 1 and 2 (FAR1/2). This reaction p duces
the first ether lipid precursor, alkyl-DHAP. (3) A membrane-spanning enzyme, peroxisome reductase
activating PPARγ (PexRAP), redu es alkyl-DHAP and acyl-DHAP to lkyl-LPA (Fi ure 1b) and
acyl-LPA respectively, before transporting these products into the ER for further processing. (4) Al l-
LPA is dephosphor lated and acylated at sn-2 in the ER to form alkylacylglycerol or AAG. (5) The
ethanolamine phosphotransferase EPT1 adds a phosphatidyl th nolami e (PE) gr up to AAG
using CDP-ethanolamine as the polar head group donor, which produces alkyl-PE or plasmanyl-PE.
(6) Finally, TMEM189 desaturates the ether bond at sn-1 of alkyl-PE to produce the vinyl ether bond
characteristic of plasmalogens. PC-containing plasmalogens are formed by exchange of PE for PC by
other enzymes (not shown).
The products of AGPS, various alkyl-DHAPs, are simultaneously reduced and ex-
ported from the peroxisome en route to the ER as 1-O-alkyl-2-lyso-sn-glycero-3 phosphate
or alkyllysophosphatidic acid (alkyl-LPA). Even though this pathway has been known for
quite some time, the reductase/lipid transporter responsible termed peroxisome reductase
activating PPARγ (PexRAP or DHRS7B) has only recently been identified in mice [20]. Acyl
products of GNPAT that are not substrates for AGPS can also be reduced and exported
from the peroxisome as LPA; however, most LPA is produced from lysophosphatidyl-
choline (LPC) in the blood by autotaxin, a circulating enzyme with phospholipase D-like
activity [21,22]. Alkyl-LPA is further modified in the ER, undergoing acylation at the sn-2
position by an acyltransferase distinct from GNPAT and dephosphorylation at the sn-3 po-
sition by a phosphatidate phosphatase activity. This alkylacylglycerol (AAG) intermediate
serves as a substrate for the enzyme ethanolamine phosphotransferase 1 (EPT1/SELENOI),
which uses CDP-ethanolamine to add an ethanolamine group to AAG to make alkyl-PE,
otherwise known as plasmanylethanolamine (plasmanyl-PE) [23]. EPT1 is mutated in
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certain patients with neurological disorders who display abnormal myelination of neurons
and abnormal brain development [23,24]. Skin fibroblasts isolated from these patients
showed reduced long-chain acyl-PE and alkyl-PE synthesis. Interestingly, skin fibroblasts
synthesized normal levels of the major ester-linked lipids PC and PE, yet accumulated
ether-linked PC (plasmanyl-PC), inferring that AAG substrates for EPT1 are repurposed
by choline phosphotransferases. Similar reductions in PE were detected in HeLa cells
bioengineered to lack EPT1 [23] or in yeast cells expressing human EPT1 with an R122P
point mutation, which showed greatly reduced enzymatic activity [24]. Thus, EPT1 is the
dominant enzyme responsible for long-chain plasmanyl-PE biosynthesis, which appears to
be essential for normal neurological development.
Alkyl-PE can be subsequently oxidized by plasmanylethanolamine desaturase 1 (PEDS1
or TMEM189) to create a double bond at sn-1 (vinyl ether bond) and the final product, 1-alkenyl-
PE or plasmenylethanolamine (1-(1Z-alkenyl)-2-acylglycerophosphoethanolamine) [25,26].
Similar to EPT1, TMEM189 was only recently identified, which underscores the relative lack
of attention and subsequent knowledge of ether lipid metabolism compared to the Kennedy
pathway or other well-documented acyl-lipid pathways for phospholipid biosynthesis. The
final lipid products of TMEM189 are known as plasmalogens (Figures 1c and 2), which
represents the largest group of ether lipids known in eukaryotes, estimated to be over 50% of
the total phospholipid content of certain brain regions [15]. We will return to these important
ether lipids to briefly evaluate their signaling potential at the end of this review.
Due to the substrate specificity of TMEM189, however, ether-linked-PC species are
thought to be derived from plasmenyl-PE. The phosphoethanolamine group of plasmenyl-
PE is removed by phospholipase C to yield 1-alkenyl-2-acyl-sn-glycerol, which is a substrate
for choline phosphotransferase 1 (CHPT1 or CPT1) or a related enzyme with broader
substrate usage such as choline/ethanolamine phosphotransferase 1 (CEPT1). Like EPT1,
CEPT1 can also generate alkyl-PE from AAG, but EPT1 seems to be more clinically signifi-
cant, since no disease-related mutations in CEPT1 have yet been identified [24,27].
1.2. Ether Lipid Physical Characteristics
Ether lipid biosynthesis across Archaea and Bacteria domains is distinct. Archaeal
membranes contain an abundance of unique ether lipids typified by isoprenoid chains
(Figure 1d) linked to glycerol backbones via diether bonds in a 2,3-sn-glycerol stereo-
chemistry (isoprenoid dialkylglycerol diether or isoDGD) [28]. Tetraether lipids also exist
in Archaea, with two dialkyl glycerols covalently linked by extended isoprenoid units.
Tetraethers and other alkylglycerols can be found in Bacteria as well, but these lipids
follow a 1,2-sn-glycerol stereochemistry similar to eukaryotic glycerolipids [29]. These
complex ether linkages are thought to confer reduced ion permeability, increased melting
temperature and heat resistance to archaeal and bacterial membranes. Indeed, many
thermophilic, halophilic and acidophilic species contain ether lipid-rich membranes pre-
sumably as an adaptation mechanism. Since ether lipids can be found in mesophilic and
other types of bacteria not living in extreme environments, however, ether lipids may
have attained more diverse functions beyond environmental adaptation.
As in prokaryotes, eukaryotic ether lipids are more chemically stable than their acyl
counterparts, in large part due to their resistance to lipases, which do not hydrolyze
ether bonds but readily cleave ester bonds found in most glycerolipids and phospho-
glycerolipids. Even though eukaryotes typically do not inhabit extreme environments, the
physico-chemical characteristics imparted by ether bonds may be conserved with respect
to altering membrane fluidity and dynamics. For instance, certain ether lipid precursors
such as 1-O-hexadecyl-sn-glycerol (Figure 1a; HG or MG (O-16:0/0:0/0:0)) may negatively
impact retrograde vesicular transport from the Golgi to the ER, which could potentially
reduce intracellular trafficking of endocytosed microbial toxins such as Shiga toxin [30]. This
concept of ether lipids altering the physical chemistry of biomembranes may be a central
theme for this class of lipids and has been reviewed in depth previously [14].
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1.3. Signaling Ether Lipids in Bacteria
In addition to their apparent function in the lipid bilayer, ether lipids in bacteria were
presumed until recently to be static, storage forms of energy-producing fatty acyls [9]. How-
ever, bacteria produce a wide variety of ether-linked phospholipids and alkylglycerols that
appear to play signaling roles in response to environmental stresses such as starvation. For
example, the gram-negative soil-dwelling myxobacteria (Myxococcus xanthus and Stigmatella
aurantiaca) produce fruiting bodies rich in ether lipids that aid in subsequent differentiation
into spores. In M. xanthus, two distinct metabolic pathways converge on the synthesis of
these ether lipids, starting with the formation of the saturated iso-branched fatty acid, 13-
methyltetradecanoic acid (FA(i15:0)), which is incorporated into unique branched plasmanyl
and plasmenyl phosphatidylethanolamines, including 1-O-13-methyl-1-Z-tetradecenyl-2-
(13-methyltetradecanoyl)-glycero-phosphatidylethanolamine, otherwise known as vinyl
ether lipid phosphatidylethanolamine or VEPE [9,11]. According to Ring et al., VEPE is
metabolized through several reactions to a monoalkyldiacyl triglyceride called TG1 (TG(O-
i15/i15/i15) or 1-O-(13-methyltetradecyl)-2,3-di-(13-methyltetradecanoyl) glycerol) during
nutrient deprivation experiments [11]. TG1 and other alkylglycerols accumulate under these
starvation conditions in both M. xanthus and S. aurantiaca, suggesting a conserved biosyn-
thetic pathway [8–11]. Indeed, both species of myxobacteria contain a highly homologous
cluster of “ether lipid biosynthesis” (elb) genes that appear to encode for enzymes critical for
synthesizing important ether lipids such as TG1, and other less characterized alkylglycerols.
Insertional mutagenesis of the elbD gene in both M. xanthus and S. aurantiaca showed that
TG1 formation is completely abolished after 24 h of nutrient deprivation, which correlated
with dramatically reduced fruiting body and spore development [10]. The time course
of TG1 accumulation and decline was distinct compared to other triglycerides, which is
consistent with a role for TG1 as a signaling lipid instead of an energy storage depot [31].
Further evidence for an essential role of TG1 in these developmental programs comes from
experiments in which TG1 is exogenously added to bacteria under starvation conditions. TG1
rescued fruiting body formation in M. xanthus strains engineered to lack (1) key metabolic
pathways for iC15:0 biosynthesis [11], (2) “E signals” involved in inducing sporulation [8]
or (3) multiple elb enzymes [10]. Even though these data implicate ether lipids like TG1
as essential signaling molecules needed for the execution of complex myxobacterial life
cycles, the complete metabolic pathways and molecular targets of these lipids are not yet
clear. Discovery of ether lipid targets in this system may be broadly applicable to other cell
types such as mammalian adipocytes and may therefore shed light on universal ether lipid
signaling mechanisms, especially if those targets are conserved among other prokaryotes
and eukaryotes.
1.4. Mammalian Ether Lipid Signaling: PAF
Arguably, the most prototypical ether lipid is platelet activating factor (PAF), a group of
1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholines of varying hydrocarbon length at sn-1 and
an invariable acetyl group at sn-2 (e.g., PC(O-16:0/2:0); Figure 1e). The term PAF was coined
by Benveniste and colleagues when they discovered a factor derived from peroxidase-
sensitized leukocytes that potently stimulated histamine release and aggregation of purified
rabbit platelets [32]. Because the peroxidase-reactive antibody was of the IgE class and
histological micrographs revealed massive basophil degranulation and physical association
with platelets, the “platelet activating factor” was concluded to have originated from
basophils stimulated by IgE-antigen complexes. Around the same time, other investigators
were studying potent antihypertensive effects of novel lipids termed antihypertensive polar
renomedulary lipid or antihypertensive neutral renomedulary lipid (APRL and ANRL,
respectively) [33,34]. When injected intravenously, these lipids caused acute and prolonged
reductions in the blood pressure of rats at very low concentrations. APRL later turned out
to be identical to PAF [35]. Since those seminal discoveries and the identification of the
chemical structure of PAF in 1979, there have been over 14,500 papers published on the
structure, signaling properties, pharmacology, physiology and pathophysiology of PAF in
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animal models and humans. As would be expected for such a vast research field, PAF and
the enzymes involved in PAF biosynthesis and catabolism have been the topic of several
excellent reviews [36–39].
PAF Biosynthesis and Signaling
PAF was the first signaling ether lipid discovered and has several modes of action.
PAF synthesis begins in the peroxisome (as with all ether lipids) and ends in the ER. PAF is
made in a variety of cells, including platelets, myeloid leukocytes such as basophils and
monocytes, as well as endothelial cells via two distinct pathways: a two-step remodel-
ing pathway that features cytoplasmic phospholipase A2 (cPLA2)-mediated cleavage of
PC followed by transacetylation by lyso-PAF acetyltransferase (LPCAT1; Figure 3a) [38]
and a de novo pathway using alkylglycerol intermediates first described by Snyder and
colleagues [40]. The remodeling pathway appears to predominate in leukocytes and en-
dothelial cells since genetic deficiency of cPLA2 in mice results in an almost complete loss
of PAF biosynthesis in response to the phorbol ester, phorbol myristate acetate (PMA),
or the calcium ionophore A23187 [41,42]. Since cPLA2 specifically targets arachidonyl-
containing PCs as substrates, lipid mediators derived from arachidonate (FA(20:4)) such
as eicosinoids (e.g., prostaglandins, leukotrienes, etc.) were also nearly absent in these
knockout mice, demonstrating the tight link between PAF and eicosanoid metabolism.
In the remodeling pathway, PAF can be synthesized from either arachidonyl-plasmalogens
or alkyl-arachidonyl-PC (plasmanylphosphocholine) precursors (Figure 3a). Each of these
substrates is first cleaved by cPLA2 to generate the lyso species: lysoplasmalogens or
lyso-PAF (lyso-alkyl-PC or LPC) respectively. Lysoplasmalogens then undergo a reduction
of the vinyl bond at sn-1 to form lyso-PAF at which point the two biosynthetic routes
converge and lyso-PAF becomes acetylated at sn-2 to form the final product PAF. This route
is thought to comprise the majority of PAF synthesis in response to inflammatory stimuli
and likely accounts for detectable PAF bioactivity in a variety of physiological processes
related to acute and chronic inflammation.
Unlike the remodeling pathway, the de novo route of PAF biosynthesis was originally
thought to be a constitutively active pathway that established basal levels of PAF in various
tissues. PAF de novo synthesis is initiated by the acetylation of alkyl-LPA (Figure 1b) by
an acetyl-CoA acetyltransferase to yield 1-alkyl-2-acetyl-sn-glycero-3-phosphate. This acety-
lated species is dephosphorylated by a phosphohydrolase to generate 1-alkyl-2-acetyl-sn-
glycerol (Figure 1f), which is the substrate for a microsomal choline phosphotransferase [40].
This choline phosphotransferase is dithiothreitol (DTT)-insensitive, which biochemically dis-
tinguishes it from previously characterized choline phosphotransferases that are sensitive to
DTT and that utilize DAG as a substrate [43]. Even though this DTT-insensitive choline phos-
photransferase is considered the main regulatory enzyme of the de novo pathway [40,44],
its identity is somewhat unclear, since both CHPT1 and CEPT choline phosphotransferases
can synthesize PAF in the presence of 0.1–1 mM DTT from a diradyl glycerol substrate [45].
More recent evidence indicates that inflammation can enhance the de novo pathway and
generate several ether lipid intermediates that may have signaling properties independent
of PAF [46]. Since key enzymes of the remodeling pathway were also enhanced in parallel,
however, the relative significance of the de novo PAF pathway remains obscure.
After synthesis in endothelial cells and leukocytes, PAF is transported to the plasma
membrane, where it remains largely cell-associated [47,48]. Once displayed on the surface,
it interacts with a G protein-coupled receptor (GPCR) known as the PAF receptor (PAFR or
PTAFR) on target cells such as neutrophils or platelets [49,50]. Neutrophils are “tethered”
to endothelial cells via P-selectin—P-selectin glycoprotein ligand 1 (PSGL1 or SELPLG)
interactions to facilitate PAF binding to PAFR. This novel mode of signaling has been termed
juxtacrine signaling, which distinguishes cell-cell contact from other signaling mechanisms
characterized by diffusible, secreted factors interacting with receptors on distant (endocrine),
proximal (paracrine) or autologous (autocrine) cellular targets. PAF can also be secreted
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by monocytes and operate locally via autocrine/paracrine signaling or act over longer
distances in an endocrine fashion (Figure 3b) [51–53].
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Figure 3. PAF exerts its biological effects via cell-associated/juxtacrine signaling or through secre-
tion. (a). Stimulated PAF biosynthesis occurs in cells responding to pro-inflammatory stimuli (1).
This causes calcium-dependent activation of cPLA2, which cleaves sn-2 arachidonyl groups from
ether-linked PC species (alkyl-PC) and produces alkyl-lyso-PC (alkyl-LPC), while simultaneously
initiating eicosanoid synthesis through arachidonate (2). PAF can also be derived from PC-containing
plasmalogens (not shown). (3) Finally, alkyl-LPC serves as a substrate for an acetyltransferase such
as LPCAT to generate PAF. (b). PAF can signal through several mechanisms: in endothelial cells and
certain leukocytes, PAF remains largely cell-associated and interacts with a GPCR (PAFR) on target
cells to promote signaling downstream of the Gαq and Gαi heterotrimeric G proteins. Alternatively,
PAF can be secreted and interact with PAFR locally (autocrine or paracrine) or distally (endocrine) to
stimulate inflammation.
PAFR is coupled to intracellular Gαq and Gαi heterotrimeric G proteins, which send
distinct yet synergistic signals into target cells such as leukocytes and platelets [54–57].
Upon receptor engagement, Gαq exchanges GDP for GTP, dissociates from the heterotrimer
and directly activates PLCβ, which hydrolyzes membrane lipids such as phosphatidyli-
nositol bisphosphate (PIP2) into the two classical second messenger products: inositol
trisphosphate (IP3) and the signaling lipid DAG. IP3 activates calcium channels within the
ER to transiently increase intracellular calcium levels that execute a multitude of functions
such as triggering extracellular calcium entry into the cell (store-operated calcium entry or
SOCE) [58]. In platelets, calcium activates a variety of enzymes including DAG-sensitive
isoforms of protein kinase C (PKC) and CalDAG-GEFI/RasGRP2, a guanyl-nucleotide
exchange factor for the small GTPase Rap1 [59–61]. Rap1 associates directly with talin,
an abundant cytoskeletal protein that changes the conformation of β3 and β1 integrins on
the cell surface of platelets to drive aggregation and subsequent downstream signals from
ligated integrins [62]. In immune cells, SOCE activates calcium-sensitive lipases such as
cPLA2, which is critical for eicosanoid formation and the acute inflammatory response that
is the hallmark of PAF signaling.
Metabolites 2021, 11, 41 9 of 22
In addition to Gαq, PAFR stimulates GTP loading of Gαi, but unlike the positive
signals initiated by Gαq, the predominant signal from Gαi is inhibitory. Gαi binds and
inhibits adenylate cyclase, a 12 transmembrane-spanning integral membrane protein that
catalyzes the intracellular formation of another second messenger, cyclic AMP (cAMP).
Diminished cAMP levels prevent activation of cAMP-dependent signaling molecules such
as protein kinase A (PKA) that block initial stimulatory signals coming from Gαq and other
sources. Since PKA is reported to initiate anti-inflammatory signals, the PAFR activation
of Gαi suppresses these anti-inflammatory signals while simultaneously inducing pro-
inflammatory signals through Gαq [36,38].
1.5. PAF-Like Signaling Lipids
If lipid signaling function can be inferred from molecular interactions with known
second messengers such as calcium or effector proteins such as PKC, then ether lipid
components of the PAF de novo biosynthetic pathway are an emerging class of signaling
lipids. In addition to PAF, the ether-linked PAF precursors, 1-O-hexadecyl-2-acetyl-sn-
glycerol (HAG; DG(O-16:0/2:0/0:0)), the phosphorylated species of HAG (HAGP; 1-O-
hexadecyl-2-acetyl-sn-glycero-3-phosphate; PA(O-16:0/2:0)) and alkyl-LPA have all been
shown to possess either direct or indirect signaling properties in various cell types. Some of
the more recent examples are detailed below.
1.6. HAG and HG
HAG has been reported to affect the biological activity of many cell types, including
porcine endothelial cells, human leukemia cells, smooth muscle cells and platelets [63–66].
Exogenous HAG monomers inhibit the ability of platelets to associate with each other
in a process known as aggregation [63], an essential part of blood clot formation in vivo.
HAG also blocks the platelet secretion of intracellular granules that contain secondary
agonists such as ADP, which reinforce aggregation via a positive-feedback mechanism [67].
In platelets and ovarian carcinoma cells, HAG is metabolized to HG by an enzyme known
as arylacetamide deacetylase-like 1 (AADACL1/NCEH1/KIAA1363). AADACL1 activity is
upregulated in invasive breast and ovarian cancer cells and is positively associated with cell
growth [68,69]. In addition, AADACL1 expression levels may be indicative of gastric and
pancreatic cancers [70,71]. Unlike the addition of HAG or inhibition of AADACL1 activity
with the small molecule JW480 in platelets [72], HG does not appear to affect platelet
aggregation or secretion. These data suggest that HAG but not HG is an endogenous
inhibitory lipid that regulates platelet aggregation and vesicle secretion and that AADACL1
potentially regulates these important cellular events by metabolizing HAG to HG.
The mechanism of action for HAG has been closely linked to PKC by many inde-
pendent groups. In fact, HAG may interact directly with zinc finger domains called C1
domains within certain PKC isoforms. C1 domains bind phorbol esters and DAG, which is
instrumental for PKC localization to cellular membranes and the multistep activation of
PKC kinase activity [67,73,74]. HAG and related alkylglycerol binding to C1 domains typi-
cally inhibits PKC’s ability to phosphorylate substrates in response to well-characterized
activators, such as phorbol esters, DAG or DAG mimetics like 1-oleoyl-2-acetyl-sn-glycerol
(OAG) [75–79]. The ether bond at the sn-1 position of HAG is thought to be important for
this inhibition [80], which presumably occurs through a competition with PKC activators.
Since C1 domain ligands are thought to disrupt critical autoinhibitory interactions that
keep PKC in an inactive confirmation, however, it is unclear how HAG or any other C1
domain ligand could compete for binding to PKC without relieving autoinhibition and
promoting kinase activity. Nevertheless, HAG by itself, in the absence of PKC activators,
does not stimulate PKC activity and is therefore not a DAG mimetic. Perhaps HAG in-
teracts nonproductively with PKC C1 domains and prevents/reduces DAG binding to
maintain PKC isoforms in a catalytically incompetent state. Another possibility is that ether
lipids such as HAG block PKC kinase activity by preventing PKC translocation to cellular
membranes [81,82]. For example, macrophages pretreated with HAG showed reduced
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GFP-PKCε localization to phagosomes in response to an Fcγ ligand [81]. Importantly,
engagement of Fcγ produces DAG, which is known to be required for PKCε translocation,
but this important step in the PKC activation cycle seems to be antagonized by HAG. Like-
wise, various species of alkylacylglycerols (AAG) purified from shark liver oil antagonize
phorbol ester- and calcium ionophore-mediated permeability of albumin across the plasma
membranes of cultured endothelial cells, which implies a competition with DAG at C1
domains on PKC [65].
The mechanism of HAG-mediated inhibition may be more complex than a straight-
forward competition with PKC activators, however, since HAG may also activate PKC,
at least in the presence of other molecules such as DAG or phorbol esters [74,83]. Slater et al.
showed that treatment of purified PKCα or PKCβI potentiates phorbol ester binding to a
distinct site, resulting in lower calcium requirements and slightly enhanced kinase activity.
Unlike DAG and OAG, however, HAG does not activate PKC directly in the absence of other
molecules. Consistent with this, HAG prepared in vitro from phospholipase C-mediated
cleavage of PAF stimulated a PKC-like activity in neuroblastoma cell homogenates in the
presence of phosphatidylserine (another stimulatory lipid for PKC). It is not clear, how-
ever, which PKC isoforms were present in these samples, or perhaps more importantly,
whether other kinases capable of phosphorylating the histone III substrate in the assay were
present [84]. Surprisingly, this same group also found that pretreatment with HAG, DAG or
OAG blocked phorbol ester binding to smooth muscle cells, suggesting that HAG effects
may depend on additional, unidentified cellular factors [84].
In addition to its inhibitory potential, HAG may also have weak agonist properties in
human platelets. Platelets pretreated with high concentrations of HAG exhibit modestly
enhanced aggregation and calcium flux in the presence of agonists, whereas HAG by
itself causes cytoskeletal rearrangement (shape change) in the absence of agonists [67].
One possible mechanism is that HAG is acting as an intermediate in the de novo PAF
biosynthesis pathway, leading to relatively low levels of PAF that do not strongly stimulate
platelet activation.
1.7. HAGP
Perhaps much of the seemingly discordant data surrounding HAG can be explained
by a single HAG metabolite, HAGP (Figure 1g). In cancer cells, platelets and smooth
muscle cells, HAG can be deacetylated to HG by AADACL1 [63,68,84]. In the absence
of AADACL1 activity, however, HAG can be rapidly converted to its phosphorylated
form, HAGP, by a DAG kinase-like enzyme (e.g., DGKα), in both human platelets and
ovarian carcinoma cells [67,85]. HAGP was originally discovered in rabbit platelets by
Snyder and colleagues as a major metabolite of HAG that appears within minutes of
treatment with radiolabeled HAG [40]. More recently however, the kinetics of HAG to
HAGP conversion has been correlated with inhibition of aggregation, secretion and calcium
flux in human platelets [67]. Inhibition of DGKα in these cells reversed the inhibitory
effects of HAG on platelet aggregation, indicating that the conversion of HAG to HAGP
was critical for HAG-mediated inhibition. When incorporated into lipid vesicles, HAGP
directly bound to C1a domains from PKCα and PKCδ, and both HAGP monomers and
HAGP-containing vesicles decreased phorbol ester-stimulated PKCα activity in vitro [67].
Interestingly, HAG does not appear to be phosphorylated in smooth muscle cells, which
results in PAF-like stimulation of PKC and cell proliferation rather than PKC inhibition [84].
Although additional molecular mechanisms may exist, these intriguing data suggest that
the expression level and/or activity of lipid kinases balance cellular pools of HAG and
HAGP, which in turn directly modulate PKC activity and downstream cellular events such
as aggregation/secretion in platelets and cell growth in smooth muscle cells, with increased
HAGP/HAG ratios favoring reduced PKC activity. Therefore, HAGP and HAG likely
represent novel regulatory nodes targeting PKC and perhaps other signaling molecules
during critical cellular events (Figure 4).
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exogenously added HAG is deacetylated by the serine hydrolase AADACL1 to yield its inactive
metabolite HG, which may serve as a precursor for other ether lipids and/or contribute to membrane
dynamics. In platelets and ovarian carcinoma cells, HAG can also be phosphorylated by a DGKα-like
lipid kinase to generate HAGP, which inhibits PKC activity and platelet activation (red line), likely
by interfering with DAG binding to PKC isoforms. In contrast, HAG may enhance PKC-dependent
cell growth in smooth muscle cells through an unknown mechanism (dashed line). Adapted from
Holly et al. [67]
1.8. Ether Lipids and Cancer
Other PAF-like ether lipids may control important growth circuits during tumorigen-
esis and cancer pathophysiology, since ether lipids as a class are upregulated in several
distinct types of cancer inclu ing brain, b east, ovaria and skin cancers [18,69,86,87].
Natural ether lipids may act as oncogenic ligands for GPCRs, while synthetic ether lipids
may have multiple mechanisms related to apoptosis.
1.8.1. Alkyl-LPA
Alkyl-LPA is a family of ether-linked phospholipids with radyl chains of varying
lengths and degrees of saturation that mainly differ from their more common acyl-LPA
counterparts by their alkyl linkage at sn-1 of the glycerol backbone. As mentioned earlier,
alkyl-LPA is an intermediate in the synthesis of ether lipids derived from the peroxis me,
but it is also a potent agonist at GPCRs. Much like PAF, for instance, alkyl-LPA can
potently drive platelet aggregation through ligation of endothelial differentiation gene
(EDG) receptors including LPA5 [88,89]. Since alkyl-LPA is present in the lipid core region
of atherosclerotic plaques, which upon rupture, can activate circulating platelets, it may
play a pivotal role in thrombosis [90,91].
In addition to platelet activation, alkyl-LPA has also been implicated in various aspects
of tumor progression related to cell movement [18,92]. To study the effect of ether-lipid
depletion in carcinogenesis, Benjamin et al. dramatically lowered the expression levels of
AGPS, the key enzyme that introduces the characteristic ether bond in the peroxisome that
is overexpressed in breast cancer, mela oma, primary um n tumors and Ras-transformed
cells. Upon short hairpin RNA (shRNA)-mediated knockdown of AGPS in breast 231MFP
and C8161 melanoma cells, the authors showed that both alkyl-LPA and its phospholipid
metabolites (plasmanyl and plasmenyl species of PE and PC) were reduced in these cancer
cell lines [18]. Unexpectedly, lack of AGPS activity decreased levels of non-ether lipids,
such as arachidonate, FA(20:4), and palmitate, FA(16:0), as well as eicosinoids derived from
arachidonate, such as prostaglandin E2 (PGE2). As a result of this decrease in both ether
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and acyl lipid pools, 231MFP cells were less invasive, less migratory and did not produce
tumors when transplanted into living mice in xenograft assays. Addback of alkyl-LPA
or PGE2 rescued these migration and invasion defects, whereas the addition of PAF or
other alkyl-phospholipids did not. Conversely, the overexpression of AGPS converted
benign cancer cells into more aggressive subtypes with respect to cell migration and serum-
free survival [18]. These data link both alkyl-LPA and PGE2 to an aggressive, oncogenic
phenotype, which is consistent with AGPS controlling an essential lipidomic node within
neoplastic signaling networks.
1.8.2. Synthetic Anticancer Ether Lipids
Synthetic, man-made ether lipids inspired by the structure of lysophosphatidylcholine
(LPC) have proven to be potent regulators of oncogenic cell growth [93,94]. In 1993, the syn-
thetic ether lipid known as edelfosine (1-O-hexadecyl-2-O-methyl-sn-glycero-3-phosphocholine
or ET-O-18) was shown by two groups to promote programmed cell death or apoptosis in
leukemia cells [95,96]. Eldefosine later proved to be selective for cancerous cells compared to
normal cells and thus became the prototype for the development of structurally similar drugs
with ether-linked glycerol backbones designed to fight cancer progression, two of which are
described below.
1.8.3. Edelfosine
Despite its structural similarity to PAF (methyl vs. acetyl at sn-2; Figure 1h), edelfosine
does not appear to act as a ligand for cell surface receptors that regulate calcium flux [97].
Consequently, many signaling pathways that contribute to cancer cell death such as apop-
tosis have been proposed as intracellular targets of edelfosine. Gajate et al. first showed
that edelfosine operates through pro-apoptotic mechanisms in HL-60 cells by demonstrat-
ing that edelfosine treatment disrupted mitochondrial membrane potential (∆Ψm) and
subsequent activation of caspase-3, which are components of the “intrinsic” apoptotic path-
way [98]. These authors also observed cleavage of poly(ADP-ribose) polymerase (PARP),
DNA fragmentation and cleavage of caspase-3 itself. Moreover, cell-permeable caspase
inhibitors efficiently blocked edelfosine-mediated cell death, but did not disrupt ∆Ψm in
these cells, suggesting that edelfosine’s ability to alter mitochondrial membrane integrity
lies upstream of caspase activation and intrinsic apoptosis. Similar pro-apoptotic results
were reported for edelfosine and related ether lipids in multiple leukemic cell lines [99,100].
Edelfosine has been implicated in “extrinsic apoptosis” as well, which is distinguished
from its mitochondria-centric intrinsic counterpart by the nature of the apoptotic stim-
uli. Extracellular ligands such as Fas ligand (FASLG) or tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) interact with “death receptors” such as the Fas recep-
tor/CD95 (FAS) or TRAIL receptors respectively, to trigger extrinsic apoptosis. Edelfosine
has been proposed to cluster FAS into detergent-resistant lipid rafts independently of the
natural ligand FASLG to promote extrinsic apoptosis and cancer cell death [101–103]. This
mechanism is somewhat controversial, however, since other groups have demonstrated
FAS-independent yet edelfosine-dependent modes of cell death [104,105].
In addition to apoptotic pathways, edelfosine may target ion channels such as the
calcium-gated potassium channel SK3/K(Ca)2.3, which has been implicated in cancer cell
migration [106]. Acute treatment of the highly metastatic MDA-MB-435s cell line with
10 µM eldefosine reduced the calcium sensitivity of SK3/K(Ca)2.3 and subsequent cell
migration without inhibiting the binding of apamin, a honeybee peptide known to block
SK channels, indicating an allosteric mechanism of inhibition. The polar choline group
of edelfosine is important for this activity, since neither 1-O-hexadecyl-2-O-methyl-sn-
glycerol (HMG) nor HG had any effect on cell migration in HEK cells overexpressing
SK3/K(Ca)2.3 [107].
Finally, edelfosine may disrupt signaling pathways that emanate from the most abun-
dant phospholipid in mammalian membranes, phosphatidylcholine (PC), or an equally
important group of signaling lipids, the phosphatidylinositols (PI) [108,109]. Edelfosine
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and other synthetic ether lipids incorporate into biological membranes and inhibit PC
biosynthesis in the ER, which can trigger apoptosis [109,110]. Blockade of PC and/or PI
synthesis may not only predispose cells to apoptosis, but may also decrease levels of piv-
otal signaling lipids, such as DAG and second messengers derived from lipase-dependent
hydrolysis of these phospholipids. DAG activates “conventional” and “novel” classes of
PKC isoforms, which are thought to have opposing influences on apoptosis. In general,
novel PKCs (nPKC) induce apoptosis, whereas conventional PKCs (cPKC) protect against
apoptotic stimuli [111,112]. For example, PKCδ promotes the secretion of autocrine factors
from prostate cancer cells that bind tumor necrosis factor (TNFα) and TRAIL receptors to
stimulate extrinsic apoptosis [111]. Conversely, the stimulation of PKCα, a cPKC isoform,
prevents apoptosis in bladder cancer and models of leukemia, whereas the inhibition of
cPKC isoforms triggers apoptosis [113–116].
Evidence from our lab supports this antagonistic paradigm between cPKC and nPKC
isoforms in cancer cells. In the leukemic megakaryoblastic cell line, CMK11–5 [117,118],
the bacterial metabolite and nonselective PKC inhibitor staurosporine caused caspase-
dependent intrinsic apoptosis, as measured by proteolytic cleavage of the caspase-3 sub-
strate PARP and genomic DNA fragmentation (Figure 5). Apoptosis was not reversed
by the small molecule inhibitor Gö6976, which selectively targets cPKC isoforms PKCα,
PKCβ and PKCβII, nor was apoptosis blocked by the previously mentioned ether lipid
HAG at 1–20 µM. HAG was rather inert in this system, since it neither caused nor pro-
tected against staurosporine-induced apoptosis. Interestingly, Gö6976 alone at the highest
concentration tested (10 µM) induced DNA fragmentation/ladder formation comparable
to that of staurosporine (Figure 5). These data suggest that conventional PKC isoforms
tonically protect against caspase-dependent apoptosis in megakaryocytic cells, but since
only small molecule inhibitors were used, this conclusion should be corroborated using
more selective methods (e.g., genetics).
1.8.4. Perifosine
Despite its anticancer efficacy, edelfosine caused gastrointestinal and hemolytic toxic-
ity in clinical trials, which spurred the development of safer and more effective synthetic
ether lipids [94]. One such ether lipid currently being evaluated in clinical trials targeting
various solid tumors, leukemias and lymphomas is perifosine. The structure of perifosine
varies quite significantly from edelfosine in that it lacks the entire three-carbon glycerol
backbone and has a dimethyl piperidine group in place of the phosphocholine group
of edelfosine. As might be expected from such a deviation from the original edelfosine
template, the mechanism of action for perifosine is distinct from edelfosine and involves
perturbation of the subcellular localization of the serine/threonine protein kinase, protein
kinase B (PKB/AKT). Due to the ability of AKT to antagonize apoptosis and thus pro-
mote cell survival in cancer cells, it has been the focus of an intense anticancer strategy
for many years [119]. AKT normally localizes to membranes via its pleckstrin homol-
ogy (PH) domain, which binds specific phosphatidylinositol products such as PI(3,4)P2
and PI(3,4,5)P3, which are downstream products of the lipid kinase phosphatidylinositol
3-kinase (PI3K). Membrane association facilitates activation of AKT by trans phospho-
rylation on residue T308 by phosphoinositide-dependent kinase (PDK1/PDPK1) and
on residue S473 by multiple kinases, including PDK2 and the mechanistic target of ra-
pamycin complex (mTORC). Once activated, AKT dissociates from the membrane and
phosphorylates numerous downstream effector proteins, such as the cell cycle protein p21
WAF1/CIP1 (CDKN1A) and the mitochondrial proteins BCL2-associated agonist of cell
death (BAD) and X-linked inhibitor of apoptosis (XIAP), which antagonizes apoptosis and
promotes cell survival [120,121]. Perifosine treatment of prostate cancer cells results in
subcellular mislocalization of AKT, which prevents AKT phosphorylation and subsequent
phosphorylation of downstream substrates, all of which leads to cell growth arrest [120].
Expression of a myristoylated (FA(14:0)) AKT variant rescues AKT localization and ac-
tivity, effectively bypassing perifosine-dependent inhibition of the cell cycle and growth
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arrest. Due to its ability to incorporate into membranes [109], perifosine presumably com-
petes with PIP2 and PIP3 at the AKT PH domain and prevents proper AKT localization,
resulting in reduced cell survival and increased cell death. Perifosine is currently being
tested alone and in combination with various anticancer drugs in Phase I and II trials
targeting leukemia, myeloma and other solid cancers [122].
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1.9. Ether Lipid Metabolism and Other Lipid Pathways
There are many examples of ether lipid biosynthesis pathways that impact seemingly
unrelated lipid classes. For example, the alkylglycerol products of AADACL1 (e.g., HG)
lead to the production of alkyl-LPA in cancer cells. Similar to disruption of the AGPS axis,
reduced protein expression and enzymatic activity of AADACL1 via shRNA-mediated
RNA interference lowered HG and downstream alkyl-LPA levels in ovarian carcinoma cells,
which correlated with diminished tumor volume in AADACL1-deficient tumors trans-
planted into nude mice [68]. This metabolic link may not be preserved in non-cancerous
cells, however, since murine bone marrow-derived macrophages (BMDM) pretreated with
the pharmacological inhibitor of AADACL1, JW480, show increased and not decreased
levels of alkyl-LPA [123]. JW480 decreases inflammatory cytokine production (e.g., TNFα)
at least partially through alkyl-LPA, which may be acting as an LPA receptor agonist. Inter-
estingly, JW480 treatment also upregulated sphingosine, plasmanyl-PC and plasmenyl-PC,
suggesting that AADACL1-dependent ether lipid metabolism has a broad impact on the
BMDM lipidome. Whether AADACL1 metabolizes unknown substrates besides HAG or
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whether HG synthesis impacts multiple lipid classes is not yet clear nor are the mechanisms
linking ether-linked phospholipids to cytokine production in pro-inflammatory cells.
Another example of crosstalk between lipid classes comes from cells with reduced
alkylglycerol monooxygenase (AGMO) activity. AGMO is expressed in monocytes and
macrophages and is the only enzyme capable of breaking the ether bond in alkylglycerols [124].
The reduction of AGMO protein levels and activity in a murine macrophage cell line via
RNA interference resulted in predictable increases in alkylglycerols known to be substrates
of AGMO such as HG [125]. Surprisingly though, levels of unrelated lipids belonging to the
glycosylated ceramide and cardiolipin classes were also found to be elevated, as were many
more lipids that could not be precisely identified. Interestingly, prominent ether lipids thought
to be AGMO substrates including PAF and lyso-PAF were not altered by AGMO knockdown.
Collectively, these data suggest that lowering the activity of an enzyme specifically involved
in ether lipid metabolism can have global effects on multiple lipid classes and reveal hidden
interrelationships among various biosynthetic pathways of the cellular lipidome.
1.10. Plasmalogens
As mentioned earlier, plasmalogens are the most abundant class of ether lipids and
perhaps the most clinically relevant. They have been implicated in a variety of neurological
disorders including Alzheimer’s disease, autism, epilepsy, multiple sclerosis, Parkinson’s
disease, psychiatric depression, schizophrenia and even ischemic stroke [15,126]. All of
these disorders, with the exception of epilepsy, involve reduced levels of plasmalogens in
patients, which implies a loss-of-function phenotype and a potentially protective role for
these phospholipids under normal physiological conditions. Mechanisms for plasmalogens
in the nervous system have been mostly gleaned from knockout mice that do not express
proteins required for transport into the peroxisome (e.g., PEX7) or the critical enzymes
required for ether lipid biosynthesis, AGPS or GNPAT. These mechanisms range from
proper development of essential brain regions such as the cerebellum to myelin sheath
formation in neurons [19,127–129]. Whether these phenotypes result specifically from
plasmalogen deficiency or should be attributed to other types of ether lipids or to a single
species of ether lipid is an open question.
Plasmalogen contributions to signal transduction are even less clear than their in-
fluence on neuronal physiology, but may stem from the composition of their fatty acyl
chains [13]. Both choline- and ethanolamine-containing plasmalogens are well known to
be enriched in acyl-linked PUFA at their sn-2 positions, which provide an abundant source
of fatty acid precursors upon liberation by cPLA2. Free PUFA are oxidized by several
enzyme families, such as cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome
P450s (CYP), which produce soluble eicosinoids (e.g., thromboxanes, prostaglandins and
other oxylipins) [7]. These oxylipins initiate a multitude of signaling pathways either
as extracellular, high affinity ligands for GPCRs or as intracellular modulators of down-
stream effectors. In addition to signaling, the oxidation of ether-linked PUFA may promote
iron-dependent cell death or ferroptosis in renal and ovarian cancer cells [130]. In par-
allel with PUFA derived from plasmalogens, the lysoplasmalogen backbone remaining
after cPLA2-mediated hydrolysis has been implicated in immune cell functions such as
phagocytosis [131] and “self” tolerance in the thymus [132]. Lysoplasmalogens can also be
converted to major signaling lipids, namely alkyl-LPA and PAF. Even the alkyl chain at the
sn-1 position of plasmalogens contributes to signaling, since liberation of this moiety by
AGMO or a related enzyme generates fatty aldehydes that impact c-Jun N-terminal kinase
(JNK) signaling and apoptosis [133]. Thus, the alkyl and acyl chains and the phospholipid
backbone of plasmalogens ultimately serve as membrane storage precursors for signaling
lipids released by lipase or monooxygenase activities, rather than direct components of
signal transduction cascades.
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2. Conclusions
Despite their discovery almost one hundred years ago, the primary function of ether
lipids remains in large part a mystery. It is clear that this class of lipids is ancient as
they can be found in the most primitive of Archaea that dwell in some of the harshest
environments on the planet. Their robust structure may well aid the ability of these
organisms to resist environmental stress, modulate their membrane composition and
adapt to inhospitable habitats. This cannot be their singular role, however, since they are
synthesized in organisms that do not face extreme conditions from soil-dwelling bacteria to
metazoan eukaryotic cells. In eukaryotes, ether lipids populate many different lipid classes,
including fatty acids, glycerolipids, glycerophospholipids saccharolipids and GPI-linked
lipids, performing unique functions in each. Perhaps not surprisingly, this taxonomic
diversity coupled with representation in structurally unrelated lipid classes does not
suggest a unified function for ether lipids, but rather points to a multifactorial utility.
Even though ether lipids were initially dismissed as odd constituents of lipid bilayers
that alter the physico-chemical properties of cellular membranes, it is now clear that ether
lipids dynamically participate in signal transduction pathways, among others. Ether lipids
such as PAF and alkyl-LPA are indisputable ligands for specific GPCRs and potently
elicit biological effects during complex physiological events such as inflammation and
coagulation. More recently, metabolic intermediates of PAF such as HAG and HG have
gained attention as signaling ether lipids that modulate PKC activity independent of their
contribution to PAF biosynthesis. This raises an interesting question as to whether lipid
intermediates that have dual functions are outliers or whether this represents a universal
theme that has not yet been substantiated by more relevant examples of ether lipids
impacting common signaling pathways. This question seems addressable, since the current
momentum of ether lipid research appears to be increasing. In this context, the relatively
recent discovery of the “ether lipid biosynthesis” (elb) genes in myxococci bacteria may
be a landmark achievement, perhaps akin to the discovery of GNPAT and AGPS in the
peroxisome. This area of investigation will likely open the door to more intriguing research
in that domain, which may be applicable to other organisms and vice versa.
Even within the signaling arena, there are many more open questions than answers
regarding ether lipids. For example, the metabolic fate of ether lipid precursors such as
alkylglycerol and their incorporation into cellular lipidomes has not been comprehensively
defined. Alkylglycerol metabolism has only been examined in a few cell types to date, with
platelets and smooth muscle cells metabolizing this lipid differently. Therefore, fundamental
knowledge about existing lipid biosynthetic pathways in various cell types is lacking and may
be cell type-specific. This knowledge gap is especially evident when relationships between
the ether lipidome and seemingly unrelated lipid classes are revealed by manipulation of
peroxisomal enzymes and systems approaches. Lipidomics is essential for identifying these
relationships and for generating targeted hypotheses focused on causal mechanisms and
potential metabolic overlap.
Another open signaling question is whether synthetic ether lipids can be effective
therapeutics in human patients and provide protection against neoplasia or neurodegener-
ative diseases. Evidence from a multitude of studies demonstrates the efficacy of synthetic
ether lipids in cell-based assays, xenografts and early stage clinical trials, but none have
yet achieved Food and Drug Administration (FDA) approval.
Finally, high-resolution system approaches alongside hypothesis-driven strategies are
poised to discover additional ether lipids and novel metabolic interrelationships between
ester and ether lipidomes in diverse cell types. These approaches will likely clarify existing
theories of ether lipids as dynamic membrane components, bioactive metabolites and
signaling modulators, while simultaneously expanding the physiological relevance of these
lipids beyond our current understanding.
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